FDA Vaccines & Related Biological Products Advisory Committee
Executive Summary
Also scheduled to meet Nov. 12-13 at the Bethesda Holiday Inn, 8:30 a.m. First day, the committee will discuss "a pending license application for acellular pertussis vaccine" and clinical endpoints of therapeutic vaccines for HIV- infected individuals. Lederle's Acel-Immune, developed by Takeda, was recommended for approval by the committee on Jan. 29. Second day, the committee will "discuss studies on the Japanese encephalitis vaccine." The committee also will discuss the intramural research programs of CBER's Mycoplasma Lab and Immunology Labs. Closed session scheduled on Nov. 13 from 3-4:30 p.m....